Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study

Shehab, Mohammad; Abu‐Farha, Mohamed; Alrashed, Fatema; Alfadhli, Ahmad; Alotaibi, Khazna; AlSahli, Abdulla; Thanaraj, Thangavel Alphonse; Channanath, Arshad; Ali, Hamad; Abubaker, Jehad; Al‐Mulla, Fahd

doi:10.1101/2021.10.20.21265239

Cited by 8 publications

(7 citation statements)

References 31 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, 21 studies were included in their entirety as shown in Table 1. These included 11 prospective studies, seven retrospective studies and three survey‐based studies 16–21,27–41 . The PRISMA Flow chart is shown in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

“…These included 11 prospective studies, seven retrospective studies and three survey‐based studies. 16 , 17 , 18 , 19 , 20 , 21 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 The PRISMA Flow chart is shown in Figure 1 . The study details are shown in Table 1 .…”

Section: Resultsmentioning

confidence: 99%

“…The COVID-19 pandemic is an ongoing, global public health challenge with millions of people reported infected. the IBD population, 16,19,21,28,32 however, majority of the studies were underpowered. This is the first systematic review and meta-analysis of the current data regarding the effectiveness of SARS-CoV-2 vaccines in patients with IBD, and indicates that the SARS-CoV-2 vaccination is safe and effective in eliciting a serological response in that patient population.…”

Section: Discussionmentioning

confidence: 99%

“…As a result, professional societies have recommended SARS‐CoV‐2 vaccination in the IBD population. 12 , 14 There have been numerous studies reporting the effectiveness and safety of the SARS‐CoV‐2 vaccine in the IBD population, 16 , 19 , 21 , 28 , 32 however, majority of the studies were underpowered. This is the first systematic review and meta‐analysis of the current data regarding the effectiveness of SARS‐CoV‐2 vaccines in patients with IBD, and indicates that the SARS‐CoV‐2 vaccination is safe and effective in eliciting a serological response in that patient population.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

Bhurwal

Mutneja

Bansal

et al. 2022

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Introduction: There are concerns regarding the effectiveness and safety of SARS-CoV-2 vaccine in inflammatory Bowel Disease (IBD) patients. This systematic review and meta-analysis comprehensively summarises the available literature regarding the safety and effectiveness of SARS-CoV-2 vaccine in IBD. Methods: Three independent reviewers performed a comprehensive review of all original articles describing the response of SARS-CoV-2 vaccines in patients with IBD. Primary outcomes were (1) pooled seroconversion rate SARS-CoV-2 vaccination in IBD patients (2) comparison of breakthrough COVID-19 infection rate SARS-CoV-2 vaccination in IBD patients with control cohort and (3) pooled adverse event rate of SARS-CoV-2 vaccine. All outcomes were evaluated for one and two doses of SARS-CoV-2 vaccine. Meta-regression was performed. Probability of publication bias was assessed using funnel plots and with Egger's test.Results: Twenty-one studies yielded a pooled seroconversion rate of 73.7% and 96.8% in IBD patients after one and two doses of SARS-CoV-2 vaccine respectively. Sub-group analysis revealed non-statistically significant differences between different immunosuppressive regimens for seroconversion. Meta-regression revealed that the vaccine type and study location independently influenced seroconversion rates.There was no statistically significant difference in breakthrough infection in IBD patients as compared to control after vaccination. Conclusion:In summary, the systematic review and meta-analysis suggest that SARS-CoV-2 vaccine is safe and effective in IBD patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

Bhurwal

Mutneja

Bansal

et al. 2022

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…While many studies have reported the clinical findings of hospitalised COVID‐19 patients, hospitals and healthcare staff globally remain overwhelmed. Though the development of vaccines against COVID‐19 17–20 signals hope for controlling the pandemic, tens of thousands of new cases are being reported every day and hospital staff need to be able to predict which patients are more likely to succumb to a severe form of COVID‐19, ARDS, ICU admission, or even death.…”

Section: Introductionmentioning

confidence: 99%

Development of a clinical risk score to predict death in patients with COVID‐19

Alhamar

Maddaloni

Shukry

et al. 2022

Diabetes Metabolism Res

Self Cite

View full text Add to dashboard Cite

Objective To build a clinical risk score to aid risk stratification among hospitalised COVID‐19 patients. Methods The score was built using data of 417 consecutive COVID‐19 in patients from Kuwait. Risk factors for COVID‐19 mortality were identified by multivariate logistic regressions and assigned weighted points proportional to their beta coefficient values. A final score was obtained for each patient and tested against death to calculate an Receiver‐operating characteristic curve. Youden's index was used to determine the cut‐off value for death prediction risk. The score was internally validated using another COVID‐19 Kuwaiti‐patient cohort of 923 patients. External validation was carried out using 178 patients from the Italian CoViDiab cohort. Results Deceased COVID‐19 patients more likely showed glucose levels of 7.0–11.1 mmol/L (34.4%, p < 0.0001) or >11.1 mmol/L (44.3%, p < 0.0001), and comorbidities such as diabetes and hypertension compared to those who survived (39.3% vs. 20.4% [ p = 0.0027] and 45.9% vs. 26.6% [ p = 0.0036], respectively). The risk factors for in‐hospital mortality in the final model were gender, nationality, asthma, and glucose categories (<5.0, 5.5–6.9, 7.0–11.1, or 11.1 > mmol/L). A score of ≥5.5 points predicted death with 75% sensitivity and 86.3% specificity (area under the curve (AUC) 0.901). Internal validation resulted in an AUC of 0.826, and external validation showed an AUC of 0.687. Conclusion This clinical risk score was built with easy‐to‐collect data and had good probability of predicting in‐hospital death among COVID‐19 patients.

show abstract

Postvaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease

Bronský¹,

Copova²,

Durilová³

et al. 2022

Journal of Pediatric Gastroenterology &Amp; Nutrition

View full text Add to dashboard Cite

Objectives:We prospectively compared the postvaccination immunity to messenger ribonucleic acid BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine of our pediatric patients over 12 years old with inflammatory bowel disease (IBD) to that of healthy controls and looked for predictors of its robustness. Methods: Anti-receptor binding domain, anti-spike S2, and anti-nucleocapsid immunoglobin-G (IgG) and immunoglobin-A levels were measured in 139 pediatric patients with IBD [65 fully vaccinated (2 doses), median age 16.3, interquartile range (IQR) 15.2-17.8 years, median time from vaccination (IQR) 61.0 (42.0-80.0) days] and 1744 controls (46, 37-57 years) using microblot array. Results: All IBD and control patients developed positive anti-receptor binding domain IgG antibodies at comparable titers. The proportion of observations with positive anti-spike S2 IgG was higher in patients with IBD than in controls [63% vs 21%, odds ratio 2.99 (1.51-5.90)], as was its titer [median (IQR) 485 (92-922) vs 79 [33-180] IU/mL]. Anti-receptor binding domain and anti-spike S2 IgG levels were associated with IBD status. We found an association between anti-spike S2 IgG levels and time since vaccination (β −4.85, 95% CI −7.14 to 2.71, P = 0.0001), history of SARS-CoV-2 polymerase chain reaction positivity (206.76, 95% CI 39.93-374.05, P = 0.0213), and anti-tumor necrosis factor treatment (−239.68, 95% CI −396.44-83.55, P = 0.0047). Forty-three percent of patients reported vaccination side effects (mostly mild). Forty-six percent of observations with positive anti-nucleocapsid IgG had a history of SARS-CoV-2 infection. Conclusions: Patients with IBD produced higher levels of postvaccination anti-spike S2 antibodies than controls. Previous SARS-CoV-2 infection is associated with higher production of postvaccination antibodies and antitumor necrosis factor treatment with lower production.

show abstract

Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study

Cited by 8 publications

References 31 publications

Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

Development of a clinical risk score to predict death in patients with COVID‐19

Postvaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease

Contact Info

Product

Resources

About